Manhattanville Health Care Center | |
311 W 231st Street, Bronx, New York 10463 | |
(718) 601-8400 | |
Name | Manhattanville Health Care Center |
---|---|
Location | 311 W 231st Street, Bronx, New York |
Certified By | Medicare and Medicaid |
No. of Certified Beds | 200 |
Occupancy Rate | 80.75% |
Medicare ID (CCN) | 335695 |
Legal Business Name | Manhattanville Sbv Llc |
Ownership Type | For Profit - Corporation |
NPI Number | 1821084195 |
Organization Name | MANHATTANVILLE SBV LLC |
Address | 311 W 231st St, Bronx, NY 10463 |
Phone Number | 718-601-8400 |
News Archive
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, owing to the launches of several new agents, the atrial fibrillation drug market will increase more than sevenfold from $790 million in 2008 to $6.1 billion in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.
A virus that destroys cancer cells but leaves normal cells unharmed may offer hope to those affected by squamous cell carcinoma of the lungs (SCC lung cancer), according to investigators from the Cancer Therapy & Research Center (CTRC) at the University of Texas Health Science Center at San Antonio. The CTRC has started patient enrollment in a US Phase 2 clinical trial using intravenous administration of REOLYSIN® in combination with carboplatin and paclitaxel in patients with SCC lung cancer.
At the annual meeting of the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) on 30 June 2015, the Senate of the largest research funding organisation approved recommendations for "Developing Clinical Research at German Universities Between 2015 and 2025" (available in German).
The group of 21 member countries, including Australia, Japan, Indonesia and the U.S., will meet this week to discuss a coordinated response to a global outbreak of the deadly bird flu.
About half of people 50 years and younger who have a low 10-year or short-term cardiovascular disease (CVD) risk may have a high lifetime risk, researchers report in Circulation: Journal of the American Heart Association.
› Verified 7 days ago
Ratings from Surveys (Inspections): | |
Ratings from Quality Measures: | |
Ratings from Staffing Data: | |
Overall Rating: |
---|
News Archive
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, owing to the launches of several new agents, the atrial fibrillation drug market will increase more than sevenfold from $790 million in 2008 to $6.1 billion in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.
A virus that destroys cancer cells but leaves normal cells unharmed may offer hope to those affected by squamous cell carcinoma of the lungs (SCC lung cancer), according to investigators from the Cancer Therapy & Research Center (CTRC) at the University of Texas Health Science Center at San Antonio. The CTRC has started patient enrollment in a US Phase 2 clinical trial using intravenous administration of REOLYSIN® in combination with carboplatin and paclitaxel in patients with SCC lung cancer.
At the annual meeting of the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) on 30 June 2015, the Senate of the largest research funding organisation approved recommendations for "Developing Clinical Research at German Universities Between 2015 and 2025" (available in German).
The group of 21 member countries, including Australia, Japan, Indonesia and the U.S., will meet this week to discuss a coordinated response to a global outbreak of the deadly bird flu.
About half of people 50 years and younger who have a low 10-year or short-term cardiovascular disease (CVD) risk may have a high lifetime risk, researchers report in Circulation: Journal of the American Heart Association.
› Verified 7 days ago
Number of Facility Reported Incidents | 0 |
Number of Substantiated Complaints | 0 |
Number of Fines | 1 |
Total Amount of Fines in Dollars | $12678 |
Number of Payment Denials | 0 |
Total Number of Penalties | 1 |
Experience Measure | Provider | National Avg. |
---|---|---|
Percentage of long-stay residents whose need for help with daily activities has increased | 13.02 | 14.46 |
Percentage of long-stay residents who lose too much weight | 7.69 | 5.51 |
Percentage of low risk long-stay residents who lose control of their bowels or bladder | 75.14 | 48.41 |
Percentage of long-stay residents with a catheter inserted and left in their bladder | 0.6 | 1.79 |
Percentage of long-stay residents with a urinary tract infection | 1.45 | 2.65 |
Percentage of long-stay residents who have depressive symptoms | 35.57 | 5.05 |
Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
Percentage of long-stay residents experiencing one or more falls with major injury | 2.61 | 3.36 |
Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 62.02 | 93.87 |
Percentage of long-stay residents who received an antipsychotic medication | 10.19 | 14.2 |
Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 12.5 | 83.88 |
Percentage of short-stay residents who newly received an antipsychotic medication | 2.39 | 1.79 |
Percentage of long-stay residents whose ability to move independently worsened | 17.11 | 17.09 |
Percentage of long-stay residents who received an antianxiety or hypnotic medication | 2.5 | 19.7 |
Percentage of high risk long-stay residents with pressure ulcers | 11.23 | 7.32 |
Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 93.63 | 95.98 |
Percentage of short-stay residents who made improvements in function | 49.46 | 67.99 |
Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 40.47 | 82.93 |
News Archive
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, owing to the launches of several new agents, the atrial fibrillation drug market will increase more than sevenfold from $790 million in 2008 to $6.1 billion in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.
A virus that destroys cancer cells but leaves normal cells unharmed may offer hope to those affected by squamous cell carcinoma of the lungs (SCC lung cancer), according to investigators from the Cancer Therapy & Research Center (CTRC) at the University of Texas Health Science Center at San Antonio. The CTRC has started patient enrollment in a US Phase 2 clinical trial using intravenous administration of REOLYSIN® in combination with carboplatin and paclitaxel in patients with SCC lung cancer.
At the annual meeting of the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) on 30 June 2015, the Senate of the largest research funding organisation approved recommendations for "Developing Clinical Research at German Universities Between 2015 and 2025" (available in German).
The group of 21 member countries, including Australia, Japan, Indonesia and the U.S., will meet this week to discuss a coordinated response to a global outbreak of the deadly bird flu.
About half of people 50 years and younger who have a low 10-year or short-term cardiovascular disease (CVD) risk may have a high lifetime risk, researchers report in Circulation: Journal of the American Heart Association.
› Verified 7 days ago
Schervier Nursing Care Center Location: 2975 Independence Ave, Bronx, New York 10463 Phone: (718) 548-1700 | |
The Citadel Rehab And Nursing Ctr At Kingsbridge Location: 3400 -26 Cannon Place, Bronx, New York 10463 Phone: (718) 796-8100 | |
Mosholu Parkway Nursing & Rehabilitation Center Location: 3356 Perry Avenue, Bronx, New York 10467 Phone: (718) 655-3568 | |
Williamsbridge Center For Rehabilitation And Nrsg Location: 1540 Tomlinson Avenue, Bronx, New York 10461 Phone: (718) 892-6600 |